Overview

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Assessment of the effect of BI 1356 or Placebo on prolongation of the QT interval
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fluoroquinolones
Linagliptin
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination